Phase 2 study of DS-8201a in subjects with colorectal cancer [DESTINY-CRC01]

Interventions: investigational material(s) Generic name etc : DS-8201a INN of investigational material : trastuzumab deruxtecan Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : IV solution (Once every 3 weeks, 6.4 mg/kg) control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): efficacy The objective response rate RECIST Version 1.1 Study Design: multi center, open-label, 3-cohort study